Document is current
Any future updates will be listed below
-
Authors
Koponen, Kari https://orcid.org/0000-0003-0417-107X
McDonald, Daniel https://orcid.org/0000-0003-0876-9060
Jousilahti, Pekka https://orcid.org/0000-0001-7190-0979
Meric, Guillaume https://orcid.org/0000-0001-6288-9958
Inouye, Michael https://orcid.org/0000-0001-9413-6520
Lahti, Leo https://orcid.org/0000-0001-5537-637X
Niiranen, Teemu https://orcid.org/0000-0002-7394-7487
Männistö, Satu https://orcid.org/0000-0002-8668-3046
Havulinna, Aki https://orcid.org/0000-0002-4787-8959
Knight, Rob https://orcid.org/0000-0001-7531-0087
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 28 March 2025
First Online: 11 April 2025
Declarations
:
: This study was conducted according to the guidelines laid down in the Declaration of Helsinki and the Ethical committee for research in epidemiology and public health at the Hospital District of Helsinki and Uusimaa (HUS) approved the research protocol of these studies (558/E3/2001). All participants signed the informed consent.
: TN has received speaking honoraria from Servier Finland and AstraZeneca. RK is a scientific advisory board member, and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant and scientific advisory board member for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. VS has had research collaboration with Bayer Ltd (outside the present study).
